2 results
Medicine type
Generic Remove Generic filter
Additional monitoring Remove Additional monitoring filter
Biosimilar Remove Biosimilar filter
Exceptional circumstances Remove Exceptional circumstances filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Referrals Remove Referrals filter
Withdrawn applications Remove Withdrawn applications filter
Referral type
Article 31 referrals Remove Article 31 referrals filter
Referral safety status
Yes Remove Yes filter
Referral PRAC recommendation
Variation Remove Variation filter
Risk minimisation measures Remove Risk minimisation measures filter
-
List item
Referral: Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products
capecitabine, fluorouracil, tegafur, flucytosine, associated names: Xeloda, Teysuno, Capecitabine Accord, Capecitabine Medac, Capecitabine Teva, Ecansya (previously Capecitabine Krka), Article 31 referrals
Status: European Commission final decision, opinion/position date: 30/04/2020, EC decision date: 07/07/2020, Last updated: 23/07/2020 -
List item
Referral: Quinolone- and fluoroquinolone-containing medicinal products
nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin, associated names: Quinsair, Article 31 referrals
Status: European Commission final decision, opinion/position date: 15/11/2018, EC decision date: 11/03/2019, Last updated: 19/03/2019